Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer

Abstract excerpt

Breast cancer is a heterogeneous disease. Around 70% of breast cancers are estrogen receptor-positive (ER+ve), with tamoxifen being most commonly used as an adjuvant treatment to prevent recurrence and metastasis. However, half of the patients will eventually develop tamoxifen resistance. The overexpression of c-MYC can drive the development of ER+ve breast cancer and confer tamoxifen resistance through multiple...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Monoclonal and Polyclonal Antibodies Research
• Share to Peptidase Inhibition and Analysis
• Share to RNA and protein synthesis mechanisms